First-in-class direct and covalent dual inhibitor of GTP-bound (ON) and GDP-bound (OFF) KRASG12C
Daniel Gerlach, Associate Scientific Director, Computational Biology Oncology at Boehringer Ingelheim, shared a recent article on X:
“Discovery of BBO-8520, a first-in-class direct and covalent dual inhibitor of GTP-bound (ON) and GDP-bound (OFF) KRASG12C, Cancer Discovery and American Association for Cancer Research.”
Authors: Anna E. Maciag, James P. Stice, Bin Wang, Alok K. Sharma, Albert H. Chan, Ken Lin, Devansh Singh, Marcin Dyba, Yue Yang, Saman Setoodeh, Brian P. Smith, Jin Hyun Ju, Stevan Jeknic, Dana Rabara, Zuhui Zhang, Erik K. Larsen, Dominic Esposito, John-Paul Denson, Michela Ranieri, Mary Meynardie, Sadaf Mehdizadeh, Patrick A. Alexander, Maria Abreu Blanco, David M. Turner, Rui Xu, Felice C. Lightstone, Kwok-Kin Wong, Andrew G. Stephen, Keshi Wang, Dhirendra K. Simanshu, Kerstin W. Sinkevicius, Dwight V. Nissley, Eli Wallace, Frank McCormick and Pedro J. Beltran
For more updates, follow OncoDaily.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023